Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2026 11:30 ET | Source: Robbins Geller Rudman & Dowd LLP

Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law

Ultragenyx allegedly misled investors about setrusumab’s potential Phase 3 study success in reducing fracture rates.
February 07, 2026 13:10 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR NOTICE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Ultragenyx allegedly misled investors about setrusumab’s potential Phase 3 study success in reducing fracture rates.
February 04, 2026 19:44 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead the Ultragenyx Class Action Lawsuit – RGRD Law

Ultragenyx allegedly misled investors about setrusumab’s potential Phase 3 study success in reducing fracture rates.